Incannex Healthcare Inc. Fee And Commission Income
Incannex Healthcare Inc. (IXHL) reported Fee And Commission Income of $407.82 thousand for the 12-month period ending 2022-06-30, per its 20-F filed 2023-10-31.
Discontinued › Income Statement › Other Income
ifrs-full:FeeAndCommissionIncome · last filed 2023-10-31
| Period end | Fee And Commission Income 12 month |
|---|---|
| 2022-06-30 | $407.82K 20-F · filed 2023-10-31 |
| 2021-06-30 | $97.98K 20-F · filed 2023-10-31 |
| 2020-06-30 | $145.20K 20-F · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |